With the characteristics of the "High Regulated and High Risk" Vaccine Industry, continuous efforts are needed to improve services to consumers. Bio Farma conducts various quality control (QC) procedures and ensures product quality (Quality Assurance) consistently and continuously. Quality control and assurance procedures are closely monitored continuously by the WHO-recognized National Regulatory Authority (NRA) or in Indonesia known as the Food and Drug Monitoring Agency (BPOM).

Before vaccine products are marketed, regulations and ethics regarding the health and safety impacts of vaccine products are met.

Vaccine manufacturing goes through a series of lengthy processes by complying with aspects of Clinical lots procedures, Current Good Manufacturing Practices (cGMP), Quality Control (QC) and Quality Service (QS). Before entering the commercial production stage, three rigorous clinical trials are carried out. Therefore, before vaccine products are marketed, regulations and ethics regarding the health and safety impacts of vaccine products have been met. The Company's policy towards consumers is stated in the Code of Business Conduct, namely providing quality products and services that are safe to use, providing good service and being fair without favoritism to consumers/customers and promoting products properly and correctly. Bio Farma has never violated regulations in conducting marketing communications either through advertising, promotion or sponsorship. Bio Farma's largest market segmentation in the country is the Ministry of Health, which is the buyer of vaccine products to be distributed through the Health Office in 34 provinces in Indonesia. In addition, Bio Farma also provides direct immunization services for individuals at the immunization center located in the company's premises, as well as immunization services to company employees through cooperation mechanisms with several institutions/companies (private sector).